Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × Panobinostat × Clear all

NCT01238692 2023-03-24

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Completed

42 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01261247 2022-05-24

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

41 enrolled 8 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01523834 2019-11-22